Autolus Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Gil Blum from Needham maintained a Buy rating on the stock and has a $10.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Gil Blum’s rating is based on several positive developments for Autolus Therapeutics. The recent conditional EU approval of Aucatzyl (obe-cel) for adult patients with relapsed or refractory acute lymphoblastic leukemia (ALL) is a significant milestone. This decision follows strong efficacy and safety data from the pivotal FELIX study and a favorable opinion from the Committee for Medicinal Products for Human Use (CHMP) earlier in the year.
Additionally, Aucatzyl has already received conditional approval in the U.K., with a launch expected soon. The early demand in the U.S. market, evidenced by $9 million in sales for the first quarter of 2025, further supports the positive outlook. These factors, combined with the estimated sales growth, underpin the Buy rating and a price target of $10.
According to TipRanks, Blum is an analyst with an average return of -7.9% and a 37.35% success rate. Blum covers the Healthcare sector, focusing on stocks such as Nurix Therapeutics, Sarepta Therapeutics, and Autolus Therapeutics.